Mayo Alliance Prognostic System (MAPS) Score

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10⁹/L

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
maps score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–2
  • Intermediate Risk3–4
  • High Risk5–6
Direct Clinical Answer

The Mayo Alliance Prognostic System (MAPS) Score calculates assessing prognosis of systemic mastocytosis using clinical and molecular risk factors. Key inputs include sm type. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.

Clinical Indication

The Mayo Alliance Prognostic System (MAPS) Score is indicated for bedside clinical practice to support Assesses prognosis of systemic mastocytosis using clinical and molecular risk factors. Developed at Mayo Clinic to provide contemporary risk stratification for patients with systemic mastocytosis, incorporating both clinical parameters and molecular genetic information for accurate survival prediction.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Regular reassessment recommended as disease status may change over time.

Formula & Variables:

MAPS Score = SM Type points + Age points + Platelet points + ALP points + Adverse mutations points. Maximum score 6 points (Advanced SM: 2 + Age >60: 1 + Platelets <150: 1 + Elevated ALP: 1 + Adverse mutations: 1)

Input Parameters

NameTypeRequiredDescription
sm_typestringYesType of systemic mastocytosis according to WHO classification. Indolent SM (ISM) and smoldering SM (SSM) have better prognosis than advanced SM subtypes
patient_ageintegerYesPatient age in years. Age >60 years is associated with worse prognosis in systemic mastocytosis(years)
platelet_countfloatYesPlatelet count in ×10⁹/L. Thrombocytopenia (<150 ×10⁹/L) is an adverse prognostic factor associated with advanced disease(×10⁹/L)
serum_alpstringYesSerum alkaline phosphatase level relative to normal range. Elevated ALP indicates possible liver involvement or bone disease in systemic mastocytosis
adverse_mutationsstringYesPresence of adverse mutations including ASXL1, RUNX1, and NRAS. These mutations are associated with poor prognosis and advanced disease progression

Score Interpretation & Guidance

RangeStageDescription
0–2Low RiskExcellent prognosis
3–4Intermediate RiskIntermediate prognosis
5–6High RiskPoor prognosis

Evidence-Based References (EBM)

  • Pardanani A, Reichard KK, Zblewski D, Abdelrahman RA, Wassie EA, Koschmann J, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv. 2018 Nov 27;2(21):2964-2975. doi: 10.1182/bloodadvances.2018024768.DOI: 10.1182/bloodadvances.2018024768
  • Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014 Oct;69(10):1267-74. doi: 10.1111/all.12436.DOI: 10.1111/all.12436
  • Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JN, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019 Nov;6(11):e638-e649. doi: 10.1016/S2352-3026(19)30166-8.DOI: 10.1016/S2352-3026(19)30166-8
  • Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544.DOI: 10.1182/blood-2016-03-643544

Related calculators